| 2020 | Compound | Omega-3 fatty acids | Unknown | Unknown | Periodontitis patient(n = 1, female) | No changes in systemic parameters↓ BoP, CAL, PD, and PI↓ Concentration of IFN-γ, IL-1β, and IL-6 in gingival crevicular fluid | dos Santos et al., 2020 |
| 2020 | Compound | Omega-3 fatty acids | Unknown | Unknown | Periodontitis patients(n = 30, both) | No adverse events↓ BoP, CAL, PD, and REC↓ Concentration of IL-8 and IL-17↑Concentration of IL-10↑Release of CCL4, CCL5, CCL15, CCL25 and CX3CL1 ↓ Release of CCL21, CCL26, CCL27, CXCL1, CXCL10 and CXCL16↑Concentration of FGF2 and G-CSF | Stańdo et al., 2020 |
| 2020 | Compound | Omega-3 fatty acids | Unknown | Unknown | Patients with chronic generalised moderate periodontitis (n = 76, both) | ↓ PPD, CAL, and GI | Kujur et al., 2020 |
| 2021 | Application | Chitosan brush | Unknown | Unknown | Patients undergoing fixed orthodontic therapy (n = 20, both) | No adverse events↓ Plaque bacterial count | Poornima et al., 2021 |
| 2021 | Application | COL-loaded composite | Chordata | Unknown | Periodontitis patients (n = 40, both) | ↓ PI, GI, PPD, and CAL↓ Radiographic defect depth | Deshpande et al., 2021 |
| 2021 | Compound | Alfalife | Unknown | Unknown | Periodontitis patients (n = 24, both) | ↓ BoP, CAL, and PD | Murgia & Aspriello, 2021 |
| 2022 | Application | Chitosan brush | Unknown | Unknown | Patients with stage III and IV, grade B periodontitis (n = 78, both) | No adverse event↓ BoP and PPD | Hussain et al., 2022 |
| 2022 | Extract | Alflutop® treatment after SRP | Chordata | Engraulis encrassicholus ponticus, Sprattus sprattus sprattus, & Rizeafca nordmanni | Periodontitis patients (n = 88, both) | No side effects↓ GI of the score 2 patients↓ PBI of the score 1 patients↓ Pathological TM of the score 1 patients↓ Degree of TM and PD | Pușcașu et al., 2022 |